(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.21%) $11.02
(0.56%) $0.808
(-0.95%) $93.01
@ $4.80
Issued: 14 Feb 2024 @ 09:34
Return: -13.30%
Previous signal: Feb 13 - 15:53
Previous signal:
Return: 4.07 %
Live Chart Being Loaded With Signals
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors...
Stats | |
---|---|
Today's Volume | 664 618 |
Average Volume | 930 225 |
Market Cap | 241.83M |
EPS | $0 ( 2024-03-27 ) |
Next earnings date | ( $-0.250 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.25 |
ATR14 | $0.00900 (0.22%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Connealy Pamela Ann | Buy | 328 710 | Common Stock |
2024-03-26 | Sullivan Lara | Buy | 1 071 242 | Stock Option (Right to Buy) |
2024-03-26 | Flavin John L | Buy | 35 219 | Common Stock |
2024-03-26 | Cline Darren S | Buy | 35 219 | Common Stock |
2024-03-26 | Lewis-hall Freda C | Buy | 35 219 | Common Stock |
INSIDER POWER |
---|
77.35 |
Last 91 transactions |
Buy: 19 296 822 | Sell: 29 966 464 |
Volume Correlation
Pyxis Oncology, Inc. Correlation
10 Most Positive Correlations | |
---|---|
RMRM | 0.915 |
OCUL | 0.904 |
XOG | 0.878 |
GAINL | 0.877 |
TDAC | 0.865 |
PAIC | 0.855 |
NTEC | 0.835 |
APOP | 0.833 |
LMFA | 0.831 |
SVOK | 0.83 |
10 Most Negative Correlations | |
---|---|
BOCH | -0.929 |
SHSP | -0.922 |
NETE | -0.889 |
MMAC | -0.858 |
EBTC | -0.848 |
FENC | -0.842 |
VWE | -0.841 |
FGBIP | -0.833 |
BLFY | -0.824 |
REYN | -0.822 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pyxis Oncology, Inc. Correlation - Currency/Commodity
Pyxis Oncology, Inc. Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-2.00M (0.00 %) |
EPS: | $-1.850 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $-763 000 (0.00 %) |
EPS: | $-0.350 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-677 000 (0.00 %) |
EPS: | $-0.560 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-699 000 (0.00 %) |
EPS: | $-0.410 |
Financial Reports:
No articles found.
Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators